MiNK Therapeutics advances cell therapy platform, trims debt in Q1

MiNK Therapeutics (NASDAQ:INKT) reported its first-quarter 2026 financial results and operational milestones, highlighting clinical advancement within its invariant natural killer T (iNKT) cell platform alongside successful balance sheet deleveraging.

The New York-based biopharmaceutical company announced the formal initiation of a randomized Phase 2 clinical trial evaluating its lead off-the-shelf, allogeneic iNKT cell therapy, agenT-797, in patients suffering from severe acute lung injury and critical illness.

Management confirmed that preliminary data from this clinical study remain on track for publication during the second half of 2026.

To fund its underlying clinical development without accelerating equity dilution, MiNK expanded several non-dilutive research and manufacturing collaborations.

These partnerships are designed to leverage the company’s native iNKT platform, which focuses on modulating immune responses to treat solid tumors and severe inflammatory conditions.

Financially, MiNK prioritized debt reduction during the three-month period, repaying $5.2 million of its outstanding debt obligations.

Driven by ongoing clinical trial expenses and corporate overhead, the company reported a net loss of $2.7 million for the quarter ended March 31, 2026.

The biotechnology developer concluded the first quarter with $9.5 million in cash and cash equivalents.

Executives stated that the combination of current cash reserves, ongoing cost-containment measures, and anticipated milestones from active collaborations provides the necessary financial runway to execute its immediate clinical objectives and support the upcoming data catalysts later this year.